Evidence map›Paper›PMID 26370309›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2015

Long-term follow-up for incident cirrhosis among pediatric cancer survivors with hepatitis C virus infection.

Sericea Stallings-Smith, Kevin R Krull, Tara M Brinkman, Melissa M Hudson, Rohit P Ojha

Abstract read
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sericea Stallings-SmithDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Kevin R KrullDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Tara M BrinkmanDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Melissa M HudsonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Rohit P OjhaDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: rohit.ojha@stjude.org.
St. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SUZANNE J. BAKER · 1985 to 2026
$166.9M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
HEPATITIS C IN CHILDHOOD CANCER SURVIVORSR01CA085891 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M · 1999 to 2003
$1.0M
NCI NIH HHS P30 CA021765NCI NIH HHS P30CA21765NCI NIH HHS R01 CA085891NCI NIH HHS R01CA85891-05NCI NIH HHS U01 CA195547
6 · The paper itself

Abstract

backgroundPediatric cancer patients who received blood transfusions were potentially exposed to hepatitis C virus (HCV) prior to second-generation HCV screening of blood products in 1992. Limited evidence is available about long-term incident cirrhosis in this population.

objectivesWe aimed to estimate the overall and sex-specific incidence of cirrhosis among HCV-seropositive survivors of pediatric cancer. STUDY

designWe identified 113HCV-seropositive pediatric cancer patients treated at St. Jude Children's Research Hospital between 1962 and 1997, who survived ≥5 years post-diagnosis, and were followed through 2014. Our outcome was cirrhosis determined by liver biopsy or diagnostic imaging. We used a competing-risk framework to estimate the overall and sex-specific cumulative incidence and 95% confidence limits (CL) of cirrhosis at 10-year follow-up intervals.

resultsThe median duration of follow-up was 30 years (interquartile range=28-36) post-cancer diagnosis. Cumulative incidence of cirrhosis increased at each 10-year interval from 0% after 10 years to 13% after 40 years (Ptrend<0.001). The median age at diagnosis of cirrhosis was 30 years (interquartile range=24-38). We observed a linear trend in incidence for males (Ptrend<0.001), with a cumulative incidence of 18% (95% CL: 6.1%, 34%) after 40 years. The cumulative incidence for females was 6.5% (95% CL: 0.42%, 26%) after 40 years, but we did not observe a linear trend (Ptrend=0.99).

conclusionOur results suggest that the incidence of cirrhosis is similar between HCV-seropositive pediatric cancer survivors and the general population given similar duration of follow-up, but survivors may be diagnosed with cirrhosis at an earlier age.

Indexed as

SurvivorsTransfusion ReactionAdolescentAdultChildChild, PreschoolFemaleHepatitis C, ChronicHumansIncidenceLiver CirrhosisLongitudinal StudiesMaleNeoplasmsSex FactorsYoung AdultEpidemiologyHepatitis C virusInfectionLate effectsLiver diseasePediatric cancer

Identifiers

PMID26370309
PMCPMC4570969
OpenAlexW2098141210

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.